Clinical trial · Observational
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
NCT02597179CI-TRIAL-00027289unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Metastatic Breast Cancer, Young Breast Cancer
- description
- Patients with feasible biopsy site.
Primary outcomes (1)
- measure
- Number of Participants With Mutated Genes and/or Abnormal Gene expression and/or Different Immune signature That Affect to Treatment Outcome.
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically confirmed breast cancer that is either metastatic or young breast cancer(≤ 40 years of age). 2. HER2 positive patient who failed HER2 target therapy including trastuzumab with feasible biopsy site. 3. Triple Negative Breast Cancer patient who failed standard therapy with feasible biopsy site. 4. Hormone Receptor positive patient who failed standard therapy with feasible biopsy site. 5. Age ≥ 21 years 6. Written informed consent Exclusion Criteria: 1. No feasible biopsy site 2. No written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.